Jiayu Gu
ABSTRACT
Purpose: The national drug negotiation work continues to deepen. Although the negotiation mechanism is becoming mature, there are still deficiencies. Through combing the current negotiation policy content, deficiencies are found, and suggestions for improvement are put forward on this basis. Method: Use the policy comparison method to sort out the contents of the five rounds of national drug negotiations, find out the points to be improved in the policy, and then use the literature search method to put forward suggestions for improvement. Result: The current national drug negotiation work is constantly improving, but there are still shortcomings, such as the issue of reciprocity in the negotiation and the lack of rare disease drugs in the catalog. Conclusion: Dynamic drug price adjustments, third-party regulatory agencies, and special protection for rare diseases have important reference significance for solving the current deficiencies in the country's drug negotiation work
- TANG, M., SONG, P. and HE, J. 2019. Progress on drug pricing negotiations in China. BioScience Trends, 13(6), pp.464-468.Google Scholar
- FAN, C., WANG, L., and WU, J. 2020. Discussion on improving the access of innovative drugs under the background of dynamic adjustment of medical insurance catalogue. China Health Insurance, (05):63-67.Google Scholar
- WANG, H., CONG, L., XIE, C., WANG, M., LIU, X., AND JIN, C. 2021. Progress and Reflection on the reform of medical insurance payment for innovative drugs in China, Health Economics Research ,38(01):47-49.Google Scholar
- The Work Plan for the Adjustment of the National Medical Insurance Drug Catalogue (Draft for Comments), 2020. National Healthcare Security Administration, China.Google Scholar
- ZHANG, M. 2017. Decryption of national drug negotiations. China Social Security, 2(08):16-19.Google Scholar
- YU, X. 2018. National Medical Insurance Bureau: the introduction of anticancer drugs into medical insurance will be implemented by the end of November. Beijing News Today. http://www.myzaker.com/article/5bbf494c77ac644863233705Google Scholar
- YU, X. 2018. National Medical Insurance Bureau: the introduction of anticancer drugs into medical insurance will be implemented by the end of November. Beijing News Today. http://www.myzaker.com/article/5bbf494c77ac644863233705Google Scholar
- Seven key points of drug price negotiation of National Health Commission of the People's Republic of China. 2015. YIYAO XINWEN PINDAO. http://www.zbsjw.cn/news/news-show-20150320000008.htmlGoogle Scholar
- Policy Interpretation of “Notice of the Ministry of human resources and social security of the state medical insurance administration on printing and distributing the catalogue of drugs for national basic medical insurance, industrial injury insurance and maternity insurance (2020).” 2020. National Healthcare Security Administration, China.Google Scholar
- DING, J. 2018. Thoughts on the special negotiation on medical insurance access of national antitumor drugs in 2018. China Health Insurance, Health Reform Policy Review. https://www.sohu.com/a/259082436_439958Google Scholar
- Official interpretation of medical insurance negotiation in 2019 by the National Medical Insurance Bureau. 2019. National Healthcare Security Administration, China. https://news.yaozh.com/archive/27791.htmlGoogle Scholar
- DING, J., WU, Y., LI, J., LI Y., AND LI, W. 2020. Analysis of the key mechanism of volume price agreement after the access of innovative drug medical insurance—Based on the practice of typical countries and parts of China. China Health Insurance, (07):75-80.Google Scholar
- LIAO, Z. 2020. Suggestions on solving the problem of drug use guarantee for patients with rare diseases. China Human Resources and Social Security, (06):59.Google Scholar
- Kim S, Lee JH. 2020. Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction. Healthcare (Basel), 8(3):233.Google Scholar
- The Pew Charitable Trusts. 2017. Payment Policies to Manage Pharmaceutical Costs. https://www.pewtrusts.org/en/research-and-analysis/reports/2017/03/payment-policies-to-manage-pharmaceutical-costsGoogle Scholar
- DING, J., WU, Y., LI, J., LI Y., AND LI, W. 2020. Analysis of the key mechanism of volume price agreement after the access of innovative drug medical insurance——Based on the practice of typical countries and parts of China. China Health Insurance, (07):75-80.Google Scholar
- NIU, R., LIU, Y., XIANG, Y., FENG, B. 2017. A comparative study of the international experience of drug price negotiation and domestic practice. Chinese Journal of Health Policy, 10(06):25-32.Google Scholar
- JIN, M., MA, A. 2019. A study on the policy of guaranteeing rare diseases and the guarantee model of supply of orphan drugs in Jiangsu Province. China Journal of Pharmaceutical Economics,14(03):93-101.Google Scholar
Recommendations
Identification of potential inhibitors against nuclear Dam1 complex subunit Ask1 of Candida albicans using virtual screening and MD simulations
Display Omitted Identified potential inhibitors of Dam1 complex subunit Ask1 of C. albicans by using clustering, virtual screening, docking & MD simulations.Developed ab-initio 3D model of C. albicans target protein Dam1 complex subunit Ask1.Identified ...
In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor
AbstractViroporins are oligomeric, pore forming, viral proteins that play critical roles in the life cycle of pathogenic viruses. Viroporins like HIV-1 Vpu, Alphavirus 6 K, Influenza M2, HCV p7, and Picornavirus 2B, form discrete aqueous ...
Highlights- Screened a database of 1806 small molecule compounds from DrugBank for potential SARS CoV-2 E protein inhibitors.
Biochemical reaction network topology defines dose-dependent Drug–Drug interactions
AbstractDrug combination therapy is a promising strategy to enhance the desired therapeutic effect, while reducing side effects. High-throughput pairwise drug combination screening is a commonly used method for discovering favorable drug interactions, ...
Highlights- Designing optimal combination therapy needs consideration of network topology, drug type, dosage, and target arrangement.
- Antagonistic interactions and the dosage of drugs are negatively correlated
- Negative feedback loops show ...
Comments